A quantitative imbalance between matrix metalloproteinases produced by cancer cells and tissue inhibitors of metalloproteinases produced by fibroblasts and other types of cells has been demonstrated to be a causative factor in invasion and metastasis of cancer cells. On the other hand, it is reported that sugar chains of adhesion molecules such as integrins and CD44 also influence the metastasis of cancer cells. Here, alterations of serum IgG oligosaccharide chain structure were investigated during tumor progression using the new method of fluorophore-assisted carbohydrate electrophoresis (FACE). The structure of serum IgG oligosaccharide chains from 22 cancer patients (11 localized cancer, 11 metastatic cancer) and 10 healthy controls was evaluated by FACE. It was clearly demonstrated that serum IgG oligosaccharide chains without galactose (agalactosyl IgG oligosaccharide) significantly increased with tumor progression of lung and gastric cancers. It is concluded that a marked increase of agalactosyl IgG oligosaccharide in these cancer patients is associated with carcinogenesis and metastasis. Therefore, the analysis of serum IgG oligosaccharide chain structure by FACE may be useful for evaluating diagnosis and prognosis in patients with these carcinomas.

Keywords:
IgG oligosaccharide chains, Agalactosyl IgG oligosaccharide, Cancers, lung and gastric
1.
Clamp JR, Putnam FW: The carbohydrate prosthetic group of human gamma-globulin. J Biol Chem 1964;239:3233–3240.
2.
Axford JS: Oligosaccharides: An optional extra of relevance to disease mechanisms in rheumatology? J Rheumatol 1991;18:1124–1127.
3.
Adler Y, Lamour A, Jamin C, Menz JR, Lecorre R, Shoenfeld Y, Youinou P: Impaired binding capacity of asialyl and agalactosyl IgG to Fc gamma receptors. Clin Exp Rheumatol 1995;13:315–319.
4.
Parekh RB, Dwek RA, Sutton BJ, Fernandes D, Leung A, Stanworth D, Rademacher TW, Mizucochi T, Taniguchi T, Matsuta K, Takeuchi F, Nagano T, Tiyamoto T, Kobata A: Association of rheumatoid arthritis and primary osteoarthritis with changes in glycosylation pattern of total serum IgG. Nature 1985;316:452–457.
5.
Malhotra R, Wormald MR, Rudd PM, Fischer PB, Dwek RA, Sim RB: Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein. Nat Med 1995;1:237–243.
6.
Parekh RB, Isenberg D, Rook G, Roitt I, Dewek R, Rademacher T: A comparative analysis of disease-associated changes in the galactosylation of serum IgG. J Autoimmun 1989;2:101–104.
7.
Martin K, Talukder R, Hay FC, Axford JS: Characterization of change in IgG associated oligosaccharide profiles in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis using fluorophore-linked carbohydrate electrophoresis. J Rheumatol 2001;28:1531–1536.
8.
Nishiura T, Fujii S, Kanayama Y, Nishikawa A, Tomiyama Y, Iida M, Karasuno T, Nakao H, Yonezawa T, Taniguchi N, Tarui S: Carbohydrate analysis of immunoglobulin G myeloma proteins by lectin and high performance liquid chromatography: Role of glycosyltransferases in the structures. Cancer Res 1990;50:5345–5350.
9.
Nakao H, Nishiura A, Nishiura T, Kanayama Y, Tarui S, Tanigichi N: Hypogalactosylation of immunoglobulin G sugar chains and elevated serum interleukin 6 in Castleman’s disease. Clin Chim Acta 1991;197:221–228.
10.
Allen AC, Bailey EM, Barratt J, Buck KS, Feehally J: Analysis of IgA 1 O-glycans in IgA nephropathy by fluophore-assisted carbohydrate electrophoresis. J Am Soc Nephrol 1991;10:1763–1771.
11.
Mashiko T, Shimetani K, Kanoh Y, Ohtani H: Quantitative and sequence analysis of oligosaccharide chain of human serum IgG by fluorophore-assisted carbohydrate electrophoresis. Kitasato Med 1999;29:276–280.
12.
Festuccia C, Vincentini C, Di Pasquale A: Plasminogen activator activities in short-term tissue cultures of benign prostatic hyperplasia and prostatic carcinoma. Oncol Res 1995;7:131–138.
13.
Quax PHA, Bart ACW de, Schalken JA: Plasminogen activator and matrix metalloproteinase production and extracellular matrix degradation by rat prostate cancer cells in vitro: Correlation with metastatic behavior in vivo. Prostate1997;32:196–204.
14.
Elise CK, Lance AL: Molecular insights into cancer invasion: Strategies for prevention and intervention. Cancer Res 1995;55:1856–1862.
15.
Arbelaez RLF, Bergmann U, Tuuttila A: Interaction of matrix metalloproteinases-2 and -9 with pregnancy zone protein and α2-macroglobulin. Arch Biochem Biophys 1997;347/1:62–68.
16.
Beekman B, Drijfhout JW, Ronday HK: Fluorogenic MMP activity assay for plasma including MMPs complexed to α2-macroglobulin. Ann NY Acad Sci 1999;878:150–156.
17.
Chen WT, Wang JY: Specialized surface protrusions of invasive cells, invadopodia and lamellipodia, have differential MT1-MMP, MMP-2 and TIMP-2 localization. Ann NY Acad Sci 1999;878:361–370.
18.
Kanoh Y, Akahoshi T, Ohara T, Ohtani N, Mashiko T, Ohtani S, Egawa S, Baba S: Expression of matrix-metalloproteinase-2 and prostate-specific antigen in localized and metastatic prostate cancer. Anticancer Res 2002;22:1813–1817.
19.
Kawano T, Takasaki S, Tao TW, Kobata A: Altered glycosylation of β1 integrins associated with reduced adhesiveness to fibronectin and laminin. Int J Cancer 1993;53:91–96.
20.
Dennis JW, Laferte S: Oncodevelopmental expression of GlcNacβ1–6Man α1–6Manβ1-branched asparagine-linked oligosaccharides in murine tissues and human breast carcinomas. Cancer Res 1989;49:945–950.
21.
Fujji S, Nishiura T, Nishikawa A, Miura R, Taniguchi N: Structural heterogeneity of sugar chains in immunoglobulin G. J Biol Chem 1990;265:6009–6018.
22.
Axford JS, Sumar N, Alavi A, Isenberg DA, Young A, Bodman KB, Roitt IM: Changes in normal glycosylation mechanisms in autoimmune rheumatic disease. J Clin Invest 1992;89:1021–1031.
© 2004 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.